1.27 0.00 (0.00%)
Pre-Market: 8:17AM EST
| Previous Close | 1.4000 |
| Open | 1.4700 |
| Bid | 1.25 x 3000 |
| Ask | 1.27 x 800 |
| Day's Range | 1.2700 - 1.4002 |
| 52 Week Range | 0.1700 - 2.4000 |
| Volume | 2,437,760 |
| Avg. Volume | 4,017,146 |
| Market Cap | 127.72M |
| Beta (3Y Monthly) | 3.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | Mar 18, 2019 - Mar 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
HENDERSON, NV / ACCESSWIRE / December 11, 2018 / We have found several companies releasing recent news we believe should be on your radar. Today we are highlighting: Delcath Systems, Inc. (DCTH), KushCo ...
BERKELEY HEIGHTS, NJ / ACCESSWIRE / December 10, 2018 / CorMedix Inc. (CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the New Jersey Economic Development Authority (NJEDA) has approved the Company's application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program for State Fiscal Year 2018. The approval will allow CorMedix to transfer approximately $5.4 million of the total $6.1 million in available tax benefits to an unrelated, profitable New Jersey corporation in return for approximately $5.0 million in cash, which is anticipated by the end of 2018. Closing is subject to NJEDA's typical closing conditions, which are in process.
CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / November 27, 2018 / CBD and biotech companies are on our radar this week. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Auris Medical Holding AG (EARS), CorMedix, ...
On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 11 cents. The pharmaceutical and medical device company posted revenue of $372,500 in the period. Its adjusted ...
Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 14, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing ...
BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 6, 2018 / CorMedix Inc. (NYSE: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...
CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives." Healthcare companies are taking a new and novel approach the health tech in the form of new innovation that takes the guesswork out of tracking health & reporting results. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Market activity in the United States appears to have picked up after the company's most recent announcement.
Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BERKELEY HEIGHTS, NJ / ACCESSWIRE / October 18, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today clarified that contrary to certain erroneous news reports it is not issuing any new shares in connection with the S-3 filing filed on October 15, 2018. On October 15, 2018, the Company filed a Form S-3 registration statement to register an aggregate of 15,081,634 shares of its common stock issuable upon the exercise of Series B warrants with an exercise price of $1.05 and associated Underwriter warrants with an exercise price of $0.9375, both expiring on August 10, 2022, which were issued in connection with the Company's May 2017 underwritten public offering.
The big shareholder groups in CorMedix Inc (NYSEMKT:CRMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable Read More...
BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 31, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that NYSE Regulation has accepted the Company's plan to regain compliance with the Exchange's continued listing standards set forth in Sections 1003(a)(i-iii) of the NYSE American Company Guide. CorMedix submitted its plan on July 16, 2018, and has been granted a plan period through December 16, 2019. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2018, CorMedix was notified on June 14, 2018, by the Exchange that the Company was not in compliance with Section 1003(a)(i)-(iii) related to insufficient stockholders' equity.
BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 30, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Khoso Baluch, President and Chief Executive Officer, accompanied by Paul Chew, M.D., Chief Medical Officer, will present a corporate overview with a focus on the Company's Neutrolin Phase 3 development program at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018 at the St. Regis New York Hotel in New York City.
On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 10 cents. The pharmaceutical and medical device company posted revenue of $7,600 in the period. Its adjusted revenue ...
- LOCK-IT-100 trial results positive; trial halted for efficacy - Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD), ...
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / CorMedix Inc. (NYSE American: CRMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...
BERKELEY HEIGHTS, NJ / ACCESSWIRE / August 2, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...
NEW YORK, NY / ACCESSWIRE / July 26, 2018 / It was a day of gains for both USANA Health Sciences Inc. and CorMedix. USANA reported record results for the second quarter while CorMedix announced the Data Safety Monitoring Board's positive review of the interim analysis of data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin. The company can now submit results to the Food & Drug Administration for review.
BERKELEY HEIGHTS, NJ / ACCESSWIRE / July 25, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the interim analysis of the data from the currently ongoing Phase 3 LOCK-IT-100 study for Neutrolin®. Because the pre-specified level of statistical significance was reached and efficacy had been demonstrated, the DSMB recommended the study be terminated early.
LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. Markets served include medical, agricultural, environmental, and industrial.Lined up for scanning this morning are the following equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), CorMedix Inc. (NYSE AMER: CRMD), CRISPR Therapeutics AG (NASDAQ: CRSP), and Endocyte Inc. (NASDAQ: ECYT).
LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on CRMD sign up now at www.wallstequities.com/registration. This Monday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Corcept Therapeutics Inc. (NASDAQ: CORT), CorMedix Inc. (NYSE AMER: CRMD), and CRISPR Therapeutics AG (NASDAQ: CRSP).